A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma,…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed…
An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3…
The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound …
Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a…
Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells…
